The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Can ibrutinib be used as a first-line treatment in CLL?
Stephan Stilgenbauer, MD from Ulm University, Ulm, Germany discusses the advances in novel chronic lymphocytic leukemia (CLL) treatments, a hot topic at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017, New York, NY. BTK inhibitor ibrutinib is an excellent example of a novel agent that successfully targets the biology of CLL. Prof. Stilgenbauer describes the advantages of ibrutinib in high-risk disease patients and those who have failed chemo-immunotherapy as a front-line treatment. The next question for ibrutinib is whether it can be used as a front-line treatment in younger patients who have not received any treatment.
